undamentalytics Newsletter
Sign in

Indivior Pharmaceuticals, Inc. income statement

In fiscal 2025, Indivior Pharmaceuticals, Inc. reported revenue of $1.24bn, up 4.3% on the year before, operating income of $262m (a 21.1% margin) and net income of $210m, or $1.64 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue9011,0931,1881,2391,374
Cost of revenue151174231246208
Gross profit7499199579941,168
Research and development741161079754
Selling, general and administrative466565612634554
Operating income−77−15238262558
Interest expense2735414517
Income before tax−86−14520239538
Income tax−43−19132988
Net income−42−1267210450
Diluted EPS−$0.30−$0.92$0.05$1.64$3.55
Diluted shares (average)139m137m133m128m127m
EBITDA−61−13754272565

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: INDV vs PAHCINDV vs LNTHINDV vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Indivior Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Indivior Pharmaceuticals, Inc.